{
  "data": {
    "id": "stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
    "url": "https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
    "indicator": {
      "slug": "approved-novel-drugs-in-breakthrough-therapy-programs",
      "name": "Approved novel drugs in breakthrough therapy programs",
      "definition": "Number of approved novel drugs that participated in breakthrough therapy programs during clinical development."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "period": {
      "start": "2024-01-01",
      "end": "2024-12-31",
      "type": "year"
    },
    "value": 13,
    "value_text": "13",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "National Medical Products Administration",
      "org_short_name": "NMPA",
      "org_url": "https://english.nmpa.gov.cn",
      "org_tier": 1,
      "document_title": "China approves 48 innovative drugs in 2024",
      "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm",
      "document_type": "press_release",
      "locator": "China approves 48 innovative drugs in 2024",
      "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.",
      "published_date": null,
      "accessed_at": "2026-09-17",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-17T07:16:01.811Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D",
      "bibtex": "@misc{nmpa2024approvedvn2y2d,\n  author       = {{National Medical Products Administration}},\n  title        = {China approves 48 innovative drugs in 2024},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D},\n  note         = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}"
    },
    "updated_at": "2026-09-17T07:16:01.811Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}